Stilla Launches Access Program for Industry’s First Six-Color Digital PCR System
Stilla Technologies, the company innovating the next generation of digital PCR solutions for life science research and molecular diagnostics, is pleased to announce the launch of its 6-Color Digital PCR Access Program which enables early access to the industry’s first Digital PCR system featuring six fluorescent channels for providing the highest multiplexing and detection capacity available on the market today. This represents a broad portfolio expansion of the Company’s original three-color naica® system and includes reagents and digital PCR consumables, automated analytical instrumentation, and turnkey visualization software. The commercial launch of the six-color naica® system is scheduled for Fall 2021.
“There is undeniable value in detecting and quantifying multiple mutations, viruses and biomarkers from a single sample. The cost versus depth tradeoffs of NGS make it impractical for the routine testing of many samples per day, while multiplex qPCR lacks the precise quantitation and exquisite sensitivity offered by digital PCR,” said Matthew Grow, PhD, Vice President Global Marketing and Commercial Operations, Stilla Technologies. “Stilla’s new six-color product offers biomedical researchers and clinicians an unprecedented level of digital multiplexing with no compromises in applications ranging from ultra-sensitive liquid biopsies and SARS-CoV-2 variant detection where rare targets are found in large sample volumes, to the absolute quantitation needed in testing such as DNA methylation, viral titering, and disease-related gene amplifications.”
Stilla is offering scientists an opportunity to experience the power and flexibility of 6-color Digital PCR by providing a range of options to drive their evaluations, including both hands-on or remote demonstrations of the naica® system. Researchers with existing qPCR or dPCR assays may request that their assays be tested using their own samples or opt to use an available 6-color assay from Stilla. On-site demos are available on a first come, first served basis.
“As biology becomes more and more complex, researchers increasingly require next-gen tools to unlock next-gen biological breakthroughs,” said Rémi Dangla, PhD, Cofounder and Chief Technology Officer, Stilla Technologies. “Stilla’s six-color Digital PCR aligns with the complexity of biological systems and provides scientists with a superior tool for accelerating biological insights to advance their research and discovery.”
Earlier this month, the United States District Court for the District of Massachusetts issued a settlement order of dismissal on a patent infringement suit brought against Stilla by Bio-Rad Laboratories. Under the terms of the agreement, Stilla Technologies will have access to certain Intellectual Property rights from Bio-Rad in the field of digital PCR, supporting Stilla’s strategy for full deployment of its dPCR product and services in key markets.
“We are highly encouraged by this outcome which demonstrates Stilla’s steadfast commitment to upholding integrity in all our operations while advancing technological innovation to accelerate research and improve human health,” added Dr. Dangla.
For more information on the Crystal Digital PCR™ Access Program, email demo@stillatechnologies.com or sign up online at: https://www.stillatechnologies.com/6-color-dpcr/.
About Stilla Technologies
Stilla Technologies is the global life sciences company providing a groundbreaking Crystal Digital PCR™ (dPCR) solution that enables researchers and clinicians to accelerate development of advanced genetic testing and molecular biology assays for a wide range of applications, including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing. Stilla aims to make dPCR a lab commodity for life sciences research, therapeutics and omics with its flexible naica® system, which incorporates proprietary, cutting–edge microfluidic innovations in addition to unsurpassed customer service and application support. To learn more visit www.stillatechnologies.com and connect with Stilla on social media Twitter, LinkedIn and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210728005803/en/
Contact information
Heidi Creighton
heidi.creighton@stillatechnologies.com
Mobile/Text: 978-302-1198
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 02:00:00 EET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 23:30:00 EET | Press release
Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the cornerstone of Australia’s secure military communications since IS-22’s launch in 2012. SES will build a dedicated ground segmen
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 23:05:00 EET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 21:00:00 EET | Press release
Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain and stiffness in the global Phase 3 MANEUVER study
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 20:32:00 EET | Press release
Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112241557/en/ Ricimed - Fabentech Ricimed®, an antidote against one of the most toxic natural substances in the world In addition to supportive care, and in severe situations requiring immediate administration, Ricimed® represents a new therapeutic option for the management of acute ricin intoxication. Ricin, among the most dangerous naturally occurring substances, can cause death within hours or days regardless of the route of exposure, making it a major biological threat for many countries. Having demonstrated its ability to specifically target and neutralize ricin before irreversible damage occurs, Ricimed® is an antibody-based therapy relying on poly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom